Massachusetts Financial Services CO Cyma Bay Therapeutics, Inc. Transaction History

Massachusetts Financial Services CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$2.77 - $3.64 $543,064 - $713,629	-196,052 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$3.23 - $4.6 $134,758 - $191,916	-41,721 Reduced 17.55%	196,052 $663,000
Q3 2021 Nov 10, 2021	SELL	$3.47 - $4.42 $10,829 - $13,794	-3,121 Reduced 1.3%	237,773 $868,000
Q2 2021 Aug 13, 2021	BUY	$3.94 - $4.92 $8,155 - $10,184	2,070 Added 0.87%	240,894 $1.05 Million
Q1 2021 May 13, 2021	BUY	$4.23 - $6.55 $386,922 - $599,135	91,471 Added 62.08%	238,824 $1.08 Million
Q4 2020 Feb 12, 2021	BUY	$5.73 - $9.03 $844,332 - $1.33 Million	147,353 New	147,353 $846,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.